Adherium Hits 100,000 Smartinhaler Commercial Milestone
16 August 2017: Adherium Limited (ASX:ADR), a digital health company that improves patient medication adherence and health outcomes, has recently manufactured and sold it’s 100,000th Smartinhaler™.
Manufacture of the 100,000th Smartinhaler™ represents a significant commercial milestone for the company. Adherium’s Smartinhalers have been sold and supplied in to more than 40 countries. Adherium is the world’s leading designer and manufacturer of Smartinhalers and it’s the Smartinhalers offer the broadest range for patients.
Smartinhalers are electronic sensors that attach to a patient’s prescription inhaled medicine. Once attached, the Smartinhaler™ automatically tracks medication usage and reminds the patient to take their medication as prescribed. They also automatically upload the electronic medication usage to a smartphone app where the patient or caregiver can review their usage, and to a web portal for population health management.
Adherium’s Smartinhalers are proven to improve patient outcomes, including reducing hospitalization in children. They have been used in numerous clinical programs around the world, resulting in over 70 peer reviewed journal articles in the world’s leading respiratory journals such as Thorax, and The Lancet Respiratory Medicine.
Record levels of investment have been made into digital health companies this year. At the end of H1, some $3.5B had been invested according to Rock Health’s Digital Health Funding 2017 Midyear Update.
Adherium’s CEO Arik Anderson said, “the sale of our 100,000th Smartinhaler™ shows that Adherium’s commercial roll-out is accelerating. It is one thing to design smartinhalers, but a whole different matter to manufacture and sell this number of devices”.
About Adherium
Adherium is a public traded (ASX:ADR), leading provider of medication adherence solutions. The company’s first platform application called Smartinhaler is proven to significantly increase medication adherence to preventative and maintenance inhaled medications, and to improving patient health outcomes.
Manufacture of the 100,000th Smartinhaler™ represents a significant commercial milestone for the company. Adherium’s Smartinhalers have been sold and supplied in to more than 40 countries. Adherium is the world’s leading designer and manufacturer of Smartinhalers and it’s the Smartinhalers offer the broadest range for patients.
Smartinhalers are electronic sensors that attach to a patient’s prescription inhaled medicine. Once attached, the Smartinhaler™ automatically tracks medication usage and reminds the patient to take their medication as prescribed. They also automatically upload the electronic medication usage to a smartphone app where the patient or caregiver can review their usage, and to a web portal for population health management.
Adherium’s Smartinhalers are proven to improve patient outcomes, including reducing hospitalization in children. They have been used in numerous clinical programs around the world, resulting in over 70 peer reviewed journal articles in the world’s leading respiratory journals such as Thorax, and The Lancet Respiratory Medicine.
Record levels of investment have been made into digital health companies this year. At the end of H1, some $3.5B had been invested according to Rock Health’s Digital Health Funding 2017 Midyear Update.
Adherium’s CEO Arik Anderson said, “the sale of our 100,000th Smartinhaler™ shows that Adherium’s commercial roll-out is accelerating. It is one thing to design smartinhalers, but a whole different matter to manufacture and sell this number of devices”.
About Adherium
Adherium is a public traded (ASX:ADR), leading provider of medication adherence solutions. The company’s first platform application called Smartinhaler is proven to significantly increase medication adherence to preventative and maintenance inhaled medications, and to improving patient health outcomes.